Amgen Inc. (LON:0R0T)

Market Cap	128.77B
Revenue (ttm)	26.70B
Net Income (ttm)	3.27B
Shares Out	n/a
EPS (ttm)	6.04
PE Ratio	39.41
Forward PE	n/a
Dividend	7.19 (2.42%)
Ex-Dividend Date	Feb 14, 2025

Volume	331,348
Average Volume	22,549
Open	294.73
Previous Close	294.00
Day's Range	294.10 - 296.72
52-Week Range	253.20 - 330.26
Beta	n/a
RSI	66.18
Earnings Date	Feb 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R0T

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD